Leadership

Management Team

Management Team

Jerry St. Peter

Co-Founder, Chief Executive Officer & Director

Jerry St. Peter has more than 27 years of experience in the ophthalmic sector. Prior to founding Eyevance, Mr. St. Peter was the Vice President and Head of Sun Pharmaceuticals’ newly formed Ophthalmics division.

Previously, Mr. St. Peter was the Executive Vice President and GM for Nicox’s Ophthalmic business and Senior Vice President and Head of the Ophthalmic division at Inspire Pharmaceuticals. His areas of functional expertise include General Management, Commercial, Market Access, and Business Development.

Jason Werner

Co-Founder, Chief Operating Officer

Jason Werner has a combined 15 years of experience in Ophthalmics and  Orphan Disease therapeutic markets. Prior to founding Eyevance, Mr. Werner was the vice president of commercial development and strategy at Sun Ophthalmics.

In addition, Mr. Werner held executive roles at Nicox, Inc., Foresight Therapeutics and Inspire Pharmaceuticals. His functional expertise includes Management Consulting, Business Development, M&A, New Product Planning, and Global Strategy.

Jodi Luchs, MD

Co-Medical Director

Dr. Luchs is a practicing ophthalmologist and an Associate Clinical Professor of Ophthalmology at Hofstra Northwell School of Medicine.

Dr. Luchs received fellowship training in Cornea/External Disease and Refractive Surgery at the prestigious Wills Eye Hospital in Philadelphia and is an internationally recognized lecturer and investigator with more than 100 clinical trials to his credit.

Mark Milner, MD

Co-Medical Director

Dr. Milner is a practicing ophthalmologist in Hamden, Connecticut, and an Associate Clinical Professor of Ophthalmology at Yale Medical School. He received his fellowship training in Cornea at the prestigious Francis I. Proctor Foundation in San Francisco, California.

Dr. Milner is an internationally recognized lecturer and was the lead author for Dysfunctional tear syndrome: New Strategies for Diagnosis and Treatment, published by the Cornea, External Disease, and Refractive Society (CEDARS) in 2017.